[Azaphen: a return to clinical practice].
Shinaev
N N
NN
Akzhigitov
R G
RG
D000293:Adolescent; D000328:Adult; D000368:Aged; D000525:Alprazolam / Q000008:administration & dosage / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D053961:Azabicyclo Compounds; D001883:Borderline Personality Disorder / Q000175:diagnosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D000077334:Zolpidem
D014151:Anti-Anxiety Agents; D000929:Antidepressive Agents, Tricyclic; D053961:Azabicyclo Compounds; D006993:Hypnotics and Sedatives; D010078:Oxazines; D010879:Piperazines; D011725:Pyridines; C515050:zopiclone; C100161:azaphen; D000077334:Zolpidem; D000525:Alprazolam